
Marrow's lead candidate MAR-101 aims to reactivate fetal hemoglobin in sickle cell disease and beta thalassemia through in vivo bone marrow targeting.
Used by leading pharma companies and CDMOs, the Beacon system offers an integrated end-to-end automated workflow for mammalian cell line development. Clones can be selectively enriched for unique phenotypes and multiple assays can be used to rapidly measure productivity of different antibody molecules.






